AU2003282306A1 - Compositions for cancer treatment - Google Patents
Compositions for cancer treatment Download PDFInfo
- Publication number
- AU2003282306A1 AU2003282306A1 AU2003282306A AU2003282306A AU2003282306A1 AU 2003282306 A1 AU2003282306 A1 AU 2003282306A1 AU 2003282306 A AU2003282306 A AU 2003282306A AU 2003282306 A AU2003282306 A AU 2003282306A AU 2003282306 A1 AU2003282306 A1 AU 2003282306A1
- Authority
- AU
- Australia
- Prior art keywords
- cell
- glycogen
- agent
- tumor
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42236502P | 2002-10-29 | 2002-10-29 | |
| US60/422,365 | 2002-10-29 | ||
| PCT/IB2003/005562 WO2004039412A2 (en) | 2002-10-29 | 2003-10-29 | Compositions for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003282306A1 true AU2003282306A1 (en) | 2004-05-25 |
Family
ID=32230344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003282306A Abandoned AU2003282306A1 (en) | 2002-10-29 | 2003-10-29 | Compositions for cancer treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20050202559A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1556088A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006508939A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1741821B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003282306A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2503422A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004039412A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381413B1 (en) * | 1998-04-17 | 2008-06-03 | University Of Vermont And State Agricultural College | Methods and products related to metabolic interactions in disease |
| AU2004248187A1 (en) * | 2003-06-12 | 2004-12-23 | University Of Colorado System Technology | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors |
| WO2005044275A1 (en) * | 2003-11-06 | 2005-05-19 | Cyclacel Limited | Use |
| WO2005070126A2 (en) | 2004-01-08 | 2005-08-04 | The Regents Of The University Of Colorado | Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors |
| JP5143566B2 (ja) * | 2004-12-21 | 2013-02-13 | ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド | 癌特異的抗体および細胞表面タンパク質 |
| EP1877060A2 (en) * | 2005-04-28 | 2008-01-16 | The Regents of the University of Colorado | Therapeutic bifunctional compounds |
| WO2006118821A2 (en) * | 2005-05-02 | 2006-11-09 | The Regents Of The University Of Colorado | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition |
| EP1917041A4 (en) | 2005-08-24 | 2010-09-29 | Cedars Sinai Medical Center | USE OF FRUCTOSE-BASED THERAPIES FOR CANCER TREATMENT |
| WO2007037533A1 (ja) * | 2005-09-30 | 2007-04-05 | Link Genomics, Inc. | Ppp1r3d遺伝子の治療的又は診断的用途 |
| US20090011060A1 (en) * | 2007-07-06 | 2009-01-08 | Peter Koepke | Campsiandra angustifolia extract and methods of extracting and using such extract |
| US7879369B2 (en) | 2007-09-18 | 2011-02-01 | Selvamedica, Llc | Combretum laurifolium Mart. extract and methods of extracting and using such extract |
| CA2716321A1 (en) * | 2008-02-21 | 2009-08-27 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
| JP5513492B2 (ja) | 2008-05-16 | 2014-06-04 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
| US9073985B2 (en) | 2008-07-14 | 2015-07-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods and products for treating proliferative diseases |
| EP2454273A4 (en) * | 2009-07-17 | 2012-12-26 | Carnegie Inst Of Washington | MECHANISM AND METHOD FOR REGULATING GLYCOGEN SYNTHASE-KINASE 3 (GSK3) -IMENTED KINASES |
| US8178307B2 (en) * | 2009-09-02 | 2012-05-15 | National Tsing Hua University | Methods and compositions for detection of lethal cell and uses thereof |
| EP2549863A4 (en) * | 2010-03-24 | 2014-01-01 | Univ Ohio | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORTATION |
| US20140106004A1 (en) * | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| JP5804389B2 (ja) * | 2013-01-11 | 2015-11-04 | 国立大学法人東北大学 | 運動に応答して筋肉細胞において発現変動するタンパク質及びそれらの受容体、それらをコードする遺伝子、並びにそれらを用いたスクリーニング方法 |
| EP3054996B1 (en) | 2013-10-07 | 2023-06-21 | IGL Pharma, Inc. | Process for preparing high purity therapeutic bone agents |
| US9580699B2 (en) | 2014-04-17 | 2017-02-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
| JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| KR102636537B1 (ko) | 2017-05-31 | 2024-02-15 | 울트라제닉스 파마수티컬 인코포레이티드 | 글리코겐 축적 질환 유형 iii에 대한 치료제 |
| CN110051841B (zh) * | 2019-05-28 | 2021-02-02 | 北京大学 | Nat10抑制剂在制备用于抑制hif表达的药物中的应用 |
| EP4323951A1 (en) * | 2021-04-14 | 2024-02-21 | Ventana Medical Systems, Inc. | Transformation of histochemically stained images into synthetic immunohistochemistry (ihc) images |
| CN118924748A (zh) * | 2024-07-19 | 2024-11-12 | 广州百吉生物制药有限公司 | 一种诱导实体肿瘤分化的药物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08198758A (ja) * | 1995-01-24 | 1996-08-06 | Aomori Pref Gov | グリコーゲンの癌予防剤としての用法 |
| US5939284A (en) * | 1996-12-05 | 1999-08-17 | Smithkline Beecham Corporation | Protein phosphatase 1 binding protein, R5 |
| US20030166592A1 (en) * | 1999-07-19 | 2003-09-04 | Monia Brett P. | Antisense modulation of liver glycogen phosphorylase expression |
| US6043091A (en) * | 1999-07-19 | 2000-03-28 | Isis Pharmaceuticals Inc. | Antisense modulation of liver glycogen phosphorylase expression |
| CN1425066B (zh) * | 2000-01-13 | 2010-05-26 | 杰南技术公司 | 新的stra6多肽 |
| US6323029B1 (en) * | 2000-01-19 | 2001-11-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of glycogen synthase kinase 3 beta expression |
| DE60129222T2 (de) * | 2000-05-11 | 2008-03-06 | Consejo Superior de Investigaciónes Científicas | Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 |
| IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| US20040180845A1 (en) * | 2003-03-13 | 2004-09-16 | Newgard Christopher B. | Methods and compositions for modulating glycogen synthesis and breakdown |
-
2003
- 2003-10-29 JP JP2004547934A patent/JP2006508939A/ja active Pending
- 2003-10-29 EP EP03773924A patent/EP1556088A2/en not_active Withdrawn
- 2003-10-29 CN CN2003801078446A patent/CN1741821B/zh not_active Expired - Fee Related
- 2003-10-29 CA CA002503422A patent/CA2503422A1/en not_active Abandoned
- 2003-10-29 AU AU2003282306A patent/AU2003282306A1/en not_active Abandoned
- 2003-10-29 WO PCT/IB2003/005562 patent/WO2004039412A2/en not_active Ceased
- 2003-10-29 US US10/697,700 patent/US20050202559A1/en not_active Abandoned
-
2008
- 2008-01-22 US US12/017,902 patent/US20090041740A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006508939A (ja) | 2006-03-16 |
| WO2004039412A3 (en) | 2004-11-04 |
| CN1741821B (zh) | 2011-08-10 |
| US20090041740A1 (en) | 2009-02-12 |
| EP1556088A2 (en) | 2005-07-27 |
| CN1741821A (zh) | 2006-03-01 |
| US20050202559A1 (en) | 2005-09-15 |
| WO2004039412A2 (en) | 2004-05-13 |
| CA2503422A1 (en) | 2004-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090041740A1 (en) | Cancer treatment by metabolic modulations | |
| JP2006508939A5 (cg-RX-API-DMAC7.html) | ||
| Peuget et al. | Translating p53-based therapies for cancer into the clinic | |
| Shen et al. | Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies | |
| Guy et al. | Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy | |
| Wulczyn et al. | The NF-κB/Rel and IκB gene families: mediators of immune response and inflammation | |
| Blagosklonny et al. | In vitro evaluation of a p53‐expressing adenovirus as an anti‐cancer drug | |
| Yi et al. | Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy | |
| EP1454628B1 (en) | Use of p38/JTV-1 for treating cancer | |
| Zhu et al. | Understanding the biology of bone sarcoma from early initiating events through late events in metastasis and disease progression | |
| Wang et al. | Hepatic regulator of G protein signaling 5 ameliorates nonalcoholic fatty liver disease by suppressing transforming growth factor beta–activated kinase 1–c‐Jun‐N‐terminal kinase/p38 signaling | |
| Mirzapoiazova et al. | Non–muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury | |
| WO2018161038A1 (en) | Il12 compositions and methods for immunotherapy | |
| US20090304663A1 (en) | Use of gsk-3 inhibitors for the treatment of prostate cancer | |
| Hsu et al. | Dual specificity phosphatase DUSP 6 promotes endothelial inflammation through inducible expression of ICAM‐1 | |
| JP2023509770A (ja) | 転写の調節可能な制御のための組成物及び方法 | |
| Vogel et al. | Erythropoietic and non‐erythropoietic functions of erythropoietin in mouse models | |
| EP3935077A1 (en) | Cd40l compositions and methods for tunable regulation | |
| Hao et al. | Loss of CRY2 promotes regenerative myogenesis by enhancing PAX7 expression and satellite cell proliferation | |
| JP2005504010A (ja) | 成長ホルモンおよびfoxm1bを用いた肝臓疾患および肝臓損傷の処置方法 | |
| Hatanaka et al. | Interferon‐α and antisense K‐ras RNA combination gene therapy against pancreatic cancer | |
| Chen et al. | Usp35 acts as a deubiquitinating enzyme for Id3 to promote immune escape in colorectal cancer | |
| US7160859B2 (en) | Mst1 modulation of apoptosis in cardiac tissue and modulators of Mst1 for treatment and prevention of cardiac disease | |
| US6787321B1 (en) | Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products | |
| WO2003061684A2 (en) | Tumour treatment compositions comprising hsp70 and tumour necrosis factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |